Antiretroviral therapy is one of the most effective strategies for preventing tuberculosis among people living with HIV. It significantly reduces the risk of tuberculosis, regardless of immunosuppression level, results of tuberculin tests and prevalence of drug-resistant tuberculosis in the region. The results of the retrospective cohort study conducted at the Pskov Regional AIDS Center from 2007-2016 convincingly confirmed the importance of the ART in preventing the TB development in patients with HIV. Of the 814 subjects included in the study, 590 - received ART, 305 - did not receive it. In compared groups TB was more likely developed in patients without antiretroviral therapy, RR 0,37 (95% CI 0,20-0,49), they were more likely to die of tuberculosis, RR 0,20 (95% CI 0,065-0,4), and among them more likely occurred other opportunistic diseases, RR 0,53 (95% CI 0,35-0,75). Among those receiving ARVT, tuberculosis and other opportunistic diseases developed more often in individuals with CD4<350 cells/ml, RR, respectively, 0,59 (95% CI 0,25-0,75) and 0,19 (95% CI 0,11 -0,59). Also in the group among those who died of tuberculosis all had low immune status. In patients with CD4> 350 cells/ml, there were no lethal outcomes of tuberculosis, RR 0.23 (95% CI 0.0-2.0). All rights reserved.
|Translated title of the contribution||Antiretroviral role in tuberculosis prevention among people living with Human Immunodeficiency Virus (retrospective cohort clinical study)|
|Publication status||Published - 1 Jan 2018|
Scopus subject areas
- Infectious Diseases